Biological Drugs for the Treatment of Uncontrolled Severe Asthma in
Children

Cristiana      Indolfi; Angela      Klain; Chiara   Lucia   Bencivenga; Elisabetta      D'Addio; Giulio      Dinardo; Alberto      Decimo; Michele   Miraglia   del Giudice
doi:10.2174/1573396320666230912103115
Abstract

The introduction of biological drugs for the treatment of severe allergic asthma in children, almost twenty years ago, had a substantial impact on both the pathology's clinical course and the quality of life of the patients who receive treatment. Over the years, several molecules have been developed that inhibit molecular targets involved in the pathogenesis of the asthmatic disease. Biological drugs demonstrate a significant improvement in several key clinical parameters in patients with severe asthma. In this review, we provide a concise summary of the evidence on biological therapy for children and adolescents with severe asthma.
« Previous Next »
Graphical Abstract

[1]
Ciprandi G, Cioffi L, Schiavetti I, et al. Factors associated with wheezing recurrence in clinical practice. J Asthma  2022; 1-2
 [http://dx.doi.org/10.1080/02770903.2022.2087187] [PMID: 35666209]

[2]
Ahmed H, Turner S. Severe asthma in children : A review of definitions, epidemiology, and treatment options in 2019. Pediatr Pulmonol  2019; 54(6): 778-87.
 [http://dx.doi.org/10.1002/ppul.24317] [PMID: 30884194]

[3]
Di Cicco ME, Leone M, Scavone M, et al. Intermittent and mild persistent asthma: How therapy has changed. Acta Biomed  2021; 92(S7): e2021523.
 [http://dx.doi.org/10.23750/abm.v92iS7.12422]

[4]
Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol  Published  2019; 10: 1514.
 [http://dx.doi.org/10.3389/fphys.2019.01514] [PMID: 31920718]

[5]
Hall S, Agrawal DK. Key mediators in the immunopathogenesis of allergic asthma. Int Immunopharmacol  2014; 23(1): 316-29.
 [http://dx.doi.org/10.1016/j.intimp.2014.05.034] [PMID: 24933589]

[6]
Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine  2015; 75(1): 68-78.
 [http://dx.doi.org/10.1016/j.cyto.2015.05.014] [PMID: 26070934]

[7]
Ridolo E, Pucciarini F, Nizi MC, et al. Mabs for treating asthma: Omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Hum Vaccin Immunother  2020; 16(10): 2349-56.
 [http://dx.doi.org/10.1080/21645515.2020.1753440] [PMID: 32401603]

[8]
Ferrante G, Tenero L, Piazza M, et al. Severe pediatric asthma therapy: Dupilumab. Front Pediatr  2022; 10: 963610.
 [http://dx.doi.org/10.3389/fped.2022.963610]

[9]
Marseglia GL, Licari A, Tosca MA, Ciprandi G. Biologics to treat severe asthma in children and adolescents: A practical update. Pediatr Allergy Immunol Pulmonol  2020; 33(4): 168-76.
 [http://dx.doi.org/10.1089/ped.2020.1212] [PMID: 35921565]

[10]
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J  2014; 43(2): 343-73.
 [http://dx.doi.org/10.1183/09031936.00202013] [PMID: 24337046]

[11]
Castagnoli R, Marseglia A, Brambilla I, Marseglia GL, Licari A. Severe uncontrolled asthma in children: Practical approach on diagnosis and management. Minerva Pediatr  2020; 72(3): 196-205.
 [http://dx.doi.org/10.23736/S0026-4946.20.05818-1] [PMID: 32108455]

[12]
Porcaro F, Ullmann N, Allegorico A, et al. Difficult and severe asthma in children. Children  2020; 7(12): 286.
 [http://dx.doi.org/10.3390/children7120286]

[13]
2022 GINA Main Report - Global Initiative for Asthma - GINA. 2022. Available from: https://ginasthma.org/gina-reports/ (Accessed on: 2022 Dec 24).

[14]
Summary of product characteristics.  Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer _004789_036892_RCP.pdf (Accessed on: 2022 Dec 24).

[15]
Summary of product characteristics.  Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer _003792_045676_RCP.pdf (Accessed on: 2022 Dec 24).

[16]
Summary of product characteristics.  Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer _003438_044648_RCP.pdf (Accessed on: 2022 Dec 24).

[17]
Summary of product characteristics.  Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer _002351_044992_RCP.pdf (Accessed on: 2022 Dec 24).

[18]
Summary of product characteristics.  Available from: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer _000690_045931_RCP.pdf (Accessed on: 2022 Dec 24).

[19]
Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy  2020; 50(1): 5-14.
 [http://dx.doi.org/10.1111/cea.13491] [PMID: 31505066]

[20]
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med  2018; 378(26): 2486-96.
 [http://dx.doi.org/10.1056/NEJMoa1804092] [PMID: 29782217]

[21]
Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoiddependent severe asthma. N Engl J Med  2018; 378(26): 2475-85.
 [http://dx.doi.org/10.1056/NEJMoa1804093] [PMID: 29782224]

[22]
Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): An open-label extension study. Lancet Respir Med  2022; 10(1): 11-25.
 [http://dx.doi.org/10.1016/S2213-2600(21)00322-2] [PMID: 34597534]

[23]
Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med  2021; 385(24): 2230-40.
 [http://dx.doi.org/10.1056/NEJMoa2106567] [PMID: 34879449]

[24]
Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma. Allergy  2020; 75(5): 1058-68.
 [http://dx.doi.org/10.1111/all.14268] [PMID: 32154939]

[25]
Spergel BL, Ruffner MA, Godwin BC, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol  2022; 128(5): 589-93.
 [http://dx.doi.org/10.1016/j.anai.2022.01.019] [PMID: 35085819]

[26]
Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs  2014; 16(6): 491-502.
 [http://dx.doi.org/10.1007/s40272-014-0107-z] [PMID: 25404353]

[27]
Paganin F, Mangiapan G, Proust A, et al. Lung function parameters in omalizumab responder patients: An interesting tool? Allergy  2017; 72(12): 1953-61.
 [http://dx.doi.org/10.1111/all.13202] [PMID: 28517027]

[28]
Licari A, Castagnoli R, Denicolò C, et al. Omalizumab in children with severe allergic asthma: The Italian real-life experience. Curr Respir Med Rev  2017; 13(1): 36-42.
 [http://dx.doi.org/10.2174/1573398X13666170426094536] [PMID: 29213221]

[29]
Yu L, Zhang H, Pan J, Ye L. Pediatric usage of Omalizumab: A promising one. World Allergy Organ J  2021; 14(12): 100614.
 [http://dx.doi.org/10.1016/j.waojou.2021.100614]

[30]
Corren J, Kavati A, Ortiz B, et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review. Allergy Asthma Proc  2017; 38(4): 250-63.
 [http://dx.doi.org/10.2500/aap.2017.38.4067] [PMID: 28631599]

[31]
Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. J Allergy Clin Immunol  2017; 139(5): 1431-44.
 [http://dx.doi.org/10.1016/j.jaci.2017.03.002] [PMID: 28477722]

[32]
Fu Z, Xu Y, Cai C. Efficacy and safety of omalizumab in children with moderate-to-severe asthma: A meta-analysis. J Asthma  2021; 58(10): 1350-8.
 [http://dx.doi.org/10.1080/02770903.2020.1789875] [PMID: 32602383]

[33]
Cheng L, Yang T, Ma X, et al. Effectiveness and safety studies of omalizumab in children and adolescents with moderate-to-severe asthma. J Pharm Pract  2021; 8971900211038251.
 [http://dx.doi.org/10.1177/08971900211038251] [PMID: 34384308]

[34]
Chen M, Choo E, Yoo B, et al. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities. Ann Allergy Asthma Immunol  2021; 126(6): 666-73.
 [http://dx.doi.org/10.1016/j.anai.2021.01.015] [PMID: 33465457]

[35]
Yilmaz O, Yuksel H. Where does current and future pediatric asthma treatment stand? Remodeling and inflammation: Bird’s eye view. Pediatr Pulmonol  2016; 51(12): 1422-9.
 [http://dx.doi.org/10.1002/ppul.23488] [PMID: 27233079]

[36]
Stelmach I, Majak P, Jerzyńska J, Bojo M, Cichalewski Ł, Smejda K. Letter to the editor children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: A case series from Poland. Arch Med Sci  2015; 4(4): 901-4.
 [http://dx.doi.org/10.5114/aoms.2015.48546] [PMID: 26322106]

[37]
Braido F, Corsico A, Rogkakou A, Ronzoni V, Baiardini I, Canonica GW. The relationship between allergen immunotherapy and omalizumab for treating asthma. Expert Rev Respir Med  2015; 9(2): 129-34.
 [http://dx.doi.org/10.1586/17476348.2015.1000866] [PMID: 25578528]

[38]
Incorvaia C, Mauro M, Russello M, Formigoni C, Ridolo E, Riario-Sforza . Omalizumab, an anti-immunoglobulin E antibody: State of the art. Drug Des Devel Ther  2014; 8: 197-207.
 [http://dx.doi.org/10.2147/DDDT.S49409] [PMID: 24532966]

[39]
Dávila González I, Moreno Benítez F, Quirce S. Benralizumab: A new approach for the treatment of severe eosinophilic asthma. J Investig Allergol Clin Immunol  2019; 29(2): 84-93.
 [http://dx.doi.org/10.18176/jiaci.0385] [PMID: 31017107]

[40]
Cushen B, Menzies-Gow A. Benralizumab: An updated treatment of eosinophilic asthma. Expert Rev Respir Med  2020; 14(5): 435-44.
 [http://dx.doi.org/10.1080/17476348.2020.1739526] [PMID: 32133878]

[41]
Bagnasco D, Caminati M, Ferrando M, et al. Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma. Biomed Res Int  2018; 2018: 5698212.
 [http://dx.doi.org/10.1155/2018/5698212]

[42]
Kupczyk M, Kuna P. Benralizumab: An anti-IL-5 receptor α monoclonal antibody in the treatment of asthma. Immunotherapy  2018; 10(5): 349-59.
 [http://dx.doi.org/10.2217/imt-2017-0161] [PMID: 29359607]

[43]
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. Lancet  2016; 388(10056): 2115-27.
 [http://dx.doi.org/10.1016/S0140-6736(16)31324-1] [PMID: 27609408]

[44]
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet  2016; 388(10056): 2128-41.
 [http://dx.doi.org/10.1016/S0140-6736(16)31322-8] [PMID: 27609406]

[45]
Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med  2017; 376(25): 2448-58.
 [http://dx.doi.org/10.1056/NEJMoa1703501] [PMID: 28530840]

[46]
European Medicines Agency.  Available from: https://www.ema.europa.eu/en/documents/overview/fasenra-epar-medicine-overview_en.pdf

[47]
Nucala prescribing information. 2022. Available from:www.gsk source.com/pharma/content/dam/GlaxoSmithKline/US/en/ Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFUCOMBINED.PDF (Accessed July Dec 24, 2022.).

[48]
Nucala EMA product information.  Available from:www.ema.europa.eu/en/documents/product-information/nucalaepar-productinformation_en.pdf (Accessed July Dec 24, 2022.).

[49]
Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet  2012; 380(9842): 651-9.
 [http://dx.doi.org/10.1016/S0140-6736(12)60988-X] [PMID: 22901886]

[50]
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med  2014; 371(13): 1198-207.
 [http://dx.doi.org/10.1056/NEJMoa1403290] [PMID: 25199059]

[51]
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med  2014; 371(13): 1189-97.
 [http://dx.doi.org/10.1056/NEJMoa1403291] [PMID: 25199060]

[52]
Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: A multi-center, open-label, phase IIIb study. Clin Ther  2016; 38(9): 2058-2070.e1.
 [http://dx.doi.org/10.1016/j.clinthera.2016.07.010] [PMID: 27553751]

[53]
Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol  2019; 143(5): 1742-1751.e7.
 [http://dx.doi.org/10.1016/j.jaci.2018.09.033] [PMID: 30359681]

[54]
Pediatric postmarketing pharmacovigilance review: cinqair® (Reslizumab).  Available from: https://www.fda.gov/media/114068/download
          (Accessed on: Dec 24, 2022.).

[55]
Cooper K, Frampton G, Harris P, Rose M, Chorozoglou M, Pickett K. Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: An evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics  2018; 36(5): 545-53.
 [http://dx.doi.org/10.1007/s40273-017-0608-z] [PMID: 29582406]

[56]
Teva. Cinqair (reslizumab) prescribing information.  Available from: https://hcp.cinqair.com/dosage-and-administration.aspx (Accessed Dec 24, 2022.).

[57]
Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract  2017; 5(6): 1572-1581.e3.
 [http://dx.doi.org/10.1016/j.jaip.2017.08.024] [PMID: 29122156]

[58]
Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med  2018; 197(1): 38-46.
 [http://dx.doi.org/10.1164/rccm.201707-1323OC] [PMID: 28915080]

[59]
Logan JK, Harinstein L, Mun˜oz M. Pediatric Postmarketing Pharmacovigilance Review: Cinqair (Reslizumab).  Available from: www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ UCM610723.pdf (Accessed on: Dec 24, 2022.).

[60]
Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy  2020; 75(5): 1023-42.
 [http://dx.doi.org/10.1111/all.14221] [PMID: 32034960]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1573396320666230912103115	Print ISSN 1573-3963
Publisher Name Bentham Science Publisher	Online ISSN 1875-6336
Current Pediatric Reviews

Biological Drugs for the Treatment of Uncontrolled Severe Asthma in Children

Abstract Play Pause

Graphical Abstract

Related Books

Abstract
